Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also...
📈 Technical Chart Patterns & Trend Analysis 📉
Identifying potential trading opportunities based on trend analysis:
bullish divergence can be seen oh 4h time frame
its been a while
reasons for pump:
after a long downtrend, price has formed a base above a 3 day demand block.
price has had a bullish reaction off a triple tap of support (triple bottom).
base looks to be accumulation with a bullish divergence on the daily RSI.
unusually high v
EMA's are beginning to turn upwards after much consolidation.
looking to play the...
$AFMD Target 9.62 for 28.27%
Or double position at 5.38
This one filled in pre-market… That's a pretty decent looking chart...
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
I start every position with 1% of my account and build from there as needed and as...
Contextual immersion trading strategy idea.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany.
The demand for shares of the company looks higher than the supply.
This and other conditions can cause a rise in the share price in the next days.
So I...
Bullish Pennant (46%)
Pros:
Volume during post formation
Descending volume during triangle formation
PPS above 50MA and 200MA
RS above 0 and ascending
ATR Ascending
R/R ratio above 6
250RSI above 50 and ascending
200MA ascending
Target:
PT = 12.10$
Help how ever you can to keep this alive.
Thank you to those who have donated Coins!
Always do your own due...
$AFMD subdued an early session sell off, recovering +7.78% intraday closing above the previous day's closing at $6.79. During the month, AFMD have successfully exhibited a major MA golden cross (50D vs 100D) before the breakout to its 52 weeks high, following with a +21% runaway gap closing on Monday's market session.
At the current juncture, $AFMD will be...
AFMD macd bullish cross over signal. Target 1: 4.33 (+10% 70% probability of touchc within next 30 days).
Second target: 4.88
30 days expected move: 1.77
Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
AFMD: Affimed N.V.
2019-11-07 16:01:00
Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers
While looking at the support and resistance lines, it becomes clear the support lines are more consolidated while the resistance lines have a larger spread. This leave an interpretation that there's much more room for AFMD to grow rather than to fall. Additionally, beyond the technicals the EPS for the previous quarter left investors shocked because of the...
